

GUWAHAT

BIOTECH PARK

ANNUAL R E P O R T



Foundation for Advancement of Essential Diagnostics (FAED)





ANNUAL R E P O R T CZ-LZCZ

Board of Directors

Dr Mustafa Ahmed Barbhuiya – Founder Director Anamika Baruah – Director, Administration & Communications Dr Amaj Ahmed Laskar – Director

Registrations

Section 8 Company Registration under Ministry of Corporate Affairs on Nov 19, 2018 R & D License number – 113291 DIPP Certificate - DIPP78683 CIN number- U73200AS2018NPL018870 PAN Card number- AADCF5651Q 12 A number- AADCF5651QE20214 80G number- AADCF5651QF20214 Darpan ID - AS/2021/0298848 CSR: SRN-T94944113

Registered Office

House No 11, Latakata Road Maidamgaon Bakrapara, Basistha Guwahati – 781029 Assam

Incubation Centre

Guwahati Biotech Park (GBP), Amingaon Guwahati – 781039 Assam

Contact

9864295480 (M), 9365061560 (M), 7906299636 (M) mabarbhuiya@faed.in, anamika@faed.in, amaj@faed.in Website: www.faed.in

Editorial Team

Anamika Baruah Dr. Biswajit Chakraborty

ANNUAL R E P O R T 27-1202

FAED: An outlook

Foundation for Advancement of Essential Diagnostics, in short, FAED is a Section 8 Company registered under Ministry of Corporate Affairs on Nov 19, 2018. It is a nonprofitable company with focus on rendering quality healthcare to all andcommitted to research and development in the areas of clinical laboratory management, pathology and laboratory medicine. FAED looks towards implementing Essential Diagnostics List (EDL) of World Health Organization (WHO) thereby finding out better and proper and timely diagnosis of health diseases so that patients receive accurate treatment.

Vision

To provide health care benefits to society to prevent unwanted deaths due to lack of accurate and timely diagnosis. To develop research and continuous medical education (CME) programs that cater to the local community needs and develop comprehensive evidence based 'Essential Diagnostics List' for specific regions in South East Asia.

Mission

Providing affordable and accessible diagnostic and healthcare services to the people in India and eventually entire south east Asia with the most up-to-date disease diagnostic methods to continually improve the health and well-being of the citizens beyond borders through best practices in laboratory medicine.

Core Purpose

Provide high quality laboratory medicine services for accurate and timely disease diagnosis to the vast majority of underserved population.


Core Values

Earnest servitude to better human life and health through the practice of one world one health.


Big Highly Audacious Goal

Ultimately, as a think-tank and thought-leadership organization, FAED aims to provide the policy and regulatory framework for a strong and functional evidence based laboratory medicine system in south-east Asia to maintain and sustain the quality of high value healthcare delivery following CLIA regulations and ISO medical laboratory standards.

ANNUAL R E P O R T CZ-1202



ANNUAL R E P O R T CZ-LZCZ



ANNUAL R E P O R T ZZ-120Z

Message from the Director



The year 2021 started with a positive note with the initiative of Government of India for Covid 19 vaccination. By the mid of the year all the eligible population (above 18 years of age) received vaccination.

Gradually, the Indian population showed sign of herd immunity against SARS CoV-2. Hence, the year looked hopeful and with the lifting up of lockdown in India and the other parts of the world, we heaved a sigh of relief. The situation moved towards normalcy.

On the official front of FAED, Dr. Biswajit Chakraborty was appointed as the Research Scientist and Principal Investigator. With his joining, FAED is all set for boosting up its activities in the days to come by.

FAED carried out its planned activities as well as applied for grants in this year.

I take this opportunity to thank our collaborator, Dibascan Molecular Diagnostic Laboratory, Silchar, our Incubation centre Guwahati Biotech Park, Amingaon all our friends and well-wishers for support and cooperation.

> Anamika Baruah Director, Administration & Communications FAED

ANNUAL R E P O R T CZ

Activities, Projects & Researches



Official Recruitment

In June 2021, FAED recruited its first employee: Dr. Biswajit Chakraborty as a Principal Investigator.

Dr. Biswajit Chakraborty is an experienced Medical Biotechnologist working as a Research Scientist and Principal Investigator at the Foundation for Advancement of Essential Diagnostics (FAED). Dr. Chakraborty specializes in the field of immunology and molecular diagnostics. Dr. Chakraborty earned his PhD in Biotechnology from the Department of Biotechnology, Assam University, Silchar, Assam (2012). His doctoral thesis was mainly based on immunopharmacology, which involves both in-vitro and in-vivo studies.

REPORT

COVID-19 Sero-survey

We have initiated clinical laboratory survey during early period of 2020 but it was interrupted due to Covid-19 pandemic lockdown. Dr. Chakraborty took the lead on carrying out the COVID19 survey.

In 2021, we mainly focused on designing and execution different project and apply for grants in different funding agencies. The following projects, which are submitted for grants are;

1) We designed and conducted Covid-19 sero-epidemiological survey in Cachar District of Assam and submitted grant application in ICMR for conducting greater sero-survey in entire Assam. In that project, we are aimed to fulfill the following objective within next 3 years and these are as follows;

- a) A onetime random cross-sectional household-based Covid-19 IgG/IgMserosurvey will be carried out across different age groups and a follow up cohort will be defined.
- b) A onetime random cross-sectional Covid-19 IgG/IgMsero-survey both from 1st and 2nd dose Covid-19 vaccinated people of all 33 districts will be carried out and follow up longitudinal study samples will be selected.
- c) A comparative IgG/IgMsero-positivity data analysis will be carried out among vaccinated and non-vaccinated people of entire Assam.
- d) A statistical analysis of infection rate, susceptibility of infection and herd immunity from IgG/Ig Msero-positivity data will be carried-out for age stratified population of Assam.
- e) Creation of a biorepository of select PBMC and serum samples will be collected from seropositive people for future immune-proteogenomic studies of SARS-CoV-2 infections.



REPORT

Picture 3: Different patient IgG /IgM Rapid antibody testing results

Along with this sero-survey, we will also conduct survey on quality assessment like test type, skill of staff, number of specialized staff etc. of each clinical laboratory of Assam. Basically we will focus on this survey the diagnosis quality of communicable and non-communicable diseases. Based on the need for Assam, this survey will help us to build our greater goal of creating a College of American Pathologist (CAP) accredited Advanced clinical laboratory in Guwahati Biotech park (GBP).

We have also conducted study on method comparison of two IVD kits of Covid-19 antibody on 25 positive patients after a specified period of infection and currently this work is going on. The results of Covid-19 IgG/IgM covid-19 are being collected and will be used to establish the efficacy of the tests. Projects for infectious diseases diagnostics and point of care

2) We have also submitted grant application to implement mobile clinical laboratory for infectious diseases and there specifically mentioned to implement mobile clinical laboratory for tuberculosis point of care testing. In that project, we are aiming to have following objectives;

- a) Operation of culture free, FDA approved Cepheid MDR-XDR PCR based TB testing facility for Cachar district of Assam augment 8 TB Units and 32 PHCs
- b) Supports DOTS program through our FAED for TB management in Cachar district of Assam
- c) Putting into practice of targeted antibiotic therapy against MDR, XDR and TDR TB in Cachar district of Assam
- d) Implementation of Syndromic testing of multiple infectious pathogen in a single reaction using FDA approved Bio-fire respiratory panel tool.

Successively, we are proposing a long term "FAED Model for Health System and Clinical Laboratory Improvement' for every district civil hospital in Assam in a public-private partnership model. Our goal is also to replicate it in other states in India that we are pursuing actively.

1. We have started some work on another project on anemia and submitted grant for that project. The project is "Public Health Intervention on Anemia in woman of Kamrup Rural and Cachar District through essential diagnostics tests" and it is having following objectives;

ANNUAL CREPORT

- a) Health awareness camps will be conducted at local Schools, Temples, Churches and Gurdwaras.
- b) Anemic parameters will be analyzed by rapid Point of care diagnostic kit HemoCueHb 301 System (Kit). A complete blood count (CBC) by HemoCueHb 301 System (Kit) will be done to evaluate your overall health and detect a wide range of disorders, including anemia, infection and leukemia.
- c) Analysis of frequency of anemia and assessment of health status followed by conducting health intervention models for maternal health in in woman of Kamrup and Cachar District.



PROCESS & TECHNOLOGY

	Pathogen	Traditional Method	Proposed methods
Amplification of POC HbA1c, Lipid Panel, Urine albumin to	Identification Mode	Blood test in Hospital and laboratory	Automated Abbott Afinion Point of care testing device
creatinine ratio (ACR) and C-reactive Protein (CRP) using Abbott Afinion Device in a Cassette	Early detection	Not often possible	Field based POC testing will make possible early detection
Results	Reach out to people	Not possible	Using mobile clinical laboratory it is possible
Documentation and MO will recommend patient for disease management	Elucidation of population range of diabetes Hb1Ac range	I nopulation can	
EAED Mobile Daint	of Come Mala sular	Denseminer and Disc	maatiaa Lah 6

FAED Mobile Point of Care Molecular Screening and Diagnostics Lab

Analytical and clinical performance of two point-of-care detection rapid antibody assays for SARS-CoV-2

Abstract presented at American Association of Clinical Chemistry, Annual Scientific Meeting and Lab expo, 2022; Jul 24-28, Chicago, Illinois, USA.

B. Chakraborty, S. Nath, S. Deb, A. Baruah, P. Bhattacharjee, M. Paul, R. A. Mohan, S. Duttaand M. A. Barbhuiya. Analytical andclinical performance of two point of care rapid antibody assays for SARS-CoV-2.

ANNUAL R E P O R T CZ-LZCZ

We have also conducted Covid-19 IgG/IgMsero-epidemiological study in Cachar, Karimganj and Hailakandi districts of Assam. We are currently carrying out the data analysis on over 4000 people sampled in these three districts.



(A) (B) (C) In the above pics:(A) A primary health care worker (Mr. SauravDev) collecting blood sample in Dibascan Molecular Diagnostic Laboratory, Silchar, Assam for Covid-19 IgG/ IgM Rapid Antibody Test for FAED sero-survey project. (B)Sample application in the lateral flow kit for Covid-19 IgG/IgM Rapid Antibody Test. (C) Nasopharyngeal swab sampling from a patient for COVD-19 Antigen testing.

Guwahati Biotech Park

FAED's incubator, Guwahati Biotech Park (GBP) shifted from the campus of IIT Guwahati to its own campus in Amingaon, Guwahati in Dec, 2021. As such, FAED's office cum laboratory got shifted to GBP, Amingaon.





ANNUAL R E P O R T

The Team



Dr Mustafa Ahmed Barbhuiya Founder Director



Anamika Baruah Director, Administrations & Communications



Dr Amaj Ahmed Laskar Director



Dr Biswajit Chakraborty Research Scientist & Principal Investigator

ANNUAL

Accounts Statement for the financial year 2021-22

CIN: U73200AS2018NPL018870

BALANCE SHEET AS AT 31ST MARCH 2022				
PARTICULARS		TE	AS AT 31-03-2022 (Rs)	AS AT 31-03-2021 (Rs)
i. EQUITY AND LIABILITIES (1) Shareholders' Funds (a) Share Capital (b) Reserves and Surplus (c) Money received against share warrants (2) Share application money pending allotment	2	1	-	
(3) Non-Current Liabilities (a) Long-term borrowings (b) Deferred tax liabilities (Net) (c) Other Long term liabilities (d) Long-term provisions				
(4) Current Liabilities (a) Short-term borrowings		2.2	-	41,000
(b) Trade payables(c) Other current liabilities		2.3	61,000	28,500
(d) Short-term provisions	Total		61,000	69.500
II.ASSETS (1) Non-current assets (a) Fixed assets (i) Tangible assets (iii) Intangible assets (iii) Capital work-in-progress (iv) Intangible assets under development (b) Non-current investments (c) Deferred tax assets (net) (d) Long term loans and advances (e) Other non-current assets			- - - - -	-
(2) Current assets (a) Current investments (b) Inventories (c) Trade receivables		2.4	61,000	69,500
(d) Cash and cash equivalents(e) Short-term loans and advances		2.4	-	-
(f) Other current assets	Total		61,000	69,500

The Schedules referred to above form an integral part of the Balance Sheet. In terms of our report of even date annexed.

For SALIL AGARWAL & CO. CHARTERED ACCOUNTANT FRN NO:326763E d 1 SALIL AGARMA (PROPRIETOR) Membership No:067263 UDIN:-GUWAHATI THE 1ST DAY OF JUNE, 2022

Foundation for Advancement of USTAFA AHMED BARBHUIYA Essential Diagnostics (FAED) Guwahati-781029 (Assam)

For and on behalf of the Board

DIN: 06465750

Barnah

ANAMIKA BARUAH DIRECTOR DIN: 08276501



Director Foundation for Advancement of Essential Diagnostics (FAED) Guwahati-781029 (Assam)

E. The Veen

TI 1/....

-

FOUNDATION FOR ADVANCEMENT OF ESSENTIAL DIAGNOSTICS CIN: U73200AS2018NPL018870

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH 2022

	PARTICULARS	NOTE	For The Year Ended 31-03-2022 (Rs)	For The Year Ended 31-03-2021 (Rs)
I.	Revenue from operations			-
II.	Donation received from Members		1,040,199.00	298,800.00
III.	Total Revenue (I +II)		1,040,199.00	298,800.00
IV.	Expenses:			
	Cost of materials consumed		-	-
	Purchase of Stock-in-Trade		-	-
	Changes in inventories of finished goods, work-in-		_	-
	progress and Stock-in-Trade			
	Employee benefit expense		612,000.00	114,000.00
	Financial costs		-	-
	Depreciation and amortization expense		-	-
	Other expenses	2.5	428,199.00	184,800.00
	Total Expenses		1,040,199.00	298,800.00
	Profit before exceptional and extraordinary items and tax (III - $IV)$		-	- -
	Exceptional Items			a second
	Profit before extraordinary items and tax (V - VI)		-	-
	. Extraordinary Items		-	-
	Profit before tax (VII - VIII)		-	-
Х.	Tax expense:			
	(1) Current tax			
	(2) Interest on Income Tax/ Service Tax			
XI.	Profit/(Loss) from the perid from continuing operations (VII - X)		· -	-
XIL	Profit/(Loss) from discontinuing operations		-	- · · · ·
	. Tax expense of discounting operations		-	-
	. Profit/(Loss) from Discontinuing operations (XII - XIII)			· · ·
χv	. Profit/(Loss) for the period $(XI + XIV)$		-	
	L Earning per equity share:			
A Y I	(1) Basic		-	-
	(1) Basic (2) Diluted		-	-
	(2) Dilated			

In terms of our report of even date annexed

For SALIL AGARWAL & CO. CHARTERED ACCOUNTANTS FRN NO:326763E

SALIL AGARWAL

ANNUAL REPORT

SALIL ACARWAL (PROPRIETOR) Membership No:067263 UDIN:-GUWAHATI <u>THE IST DAY OF JUNE, 2022</u>

Director Foundation for Advancement of Essential Diagnostics (FAED) Gu:vahati-781029 (Assam) For and on behalf of the Board

MUSTAFA AHMED BARBHUIVA

MUSTAFA AHMED BARBHUN DIRECTOR DIN: 06465750

ANAMIKA BARUAH DIRECTOR DIN: 08276501

Director Foundation for Advancement of Essential Diagnostics (FAED) Guwahati-781029 (Assam)

ANNUAL R E P O R T 27-1202

FOUNDATION FOR ADVANCEMENT OF ESSENTIAL DIAGNOSTICS CIN: U73200AS2018NPL018870 NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31,2022

a) All the figures have been rounded off to the nearest rupee.

a) Ari the indices have been regrouped/rearranged to make them more comparable with current year figures
b) Previous year figures have been regrouped/rearranged to make them more comparable with current year figures
c) Parties belance are subject to confirm ation, renconcilation and final adjustment, if any

	Parties balance are subject t		AS AT 31-03-2022 (Rs)	AS AT 31-03-2021 (Rs)
2.1	Share Capital			
	Equity Share Capital			
	Authorised Share capital		-	
	Issued, subscribed & fully	paid share capital		-
		Total	-	
			AS AT	AS AT
NOT	E PARTICULARS		31-03-2022	31-03-2021
2.2	Short Term Borrowings Loan From Related Parties		a de la composición d	41,000.00
	n en	Total	-	41,000.00
2.3	Other current liablities			10 000 00
	Audit fees payable		15,000.00	10,000.00
	Salary payable		12,000.00	9,000.00
	Rent payable		18,000.00	9,000.00
	Accounting Charges		16,000.00	-
		Total	61,000.00	28,500.00

Mem Listers PRIASE FRASE EACCOUNT Buitata And Darbhuiya MUSTAFA AHMED BARBHUIYA DIRECTOR DIN: 06465750

For and on behalf of the Board

ANAMIKA BARUAH DIRECTOR DIN: 08276501

Director Foundation for Advancement of Essential Diagnostics (FAED) Gutyahati-781029 (Assam)

Director Foundation for Advancement of Essential Diagnostics (FAED) Guwahati-781029 (Assam)

(Rs)

(Rs)

.4	Cash and cash equivalents	(10.14	826.00
	Cash in hand	642.14	835.00
	Cash at Bank	60,357.86	68.664.60
	Total	61,000.00	69,499.60
2.5	Other Expenses		
	Accounting Charges	16,000.00	
	Audit Fee	15,000.00	10,000.00
	Rent paid	108,000.00	90.473.00
	Website	-	45,884.66
	Power and Fuel	300.00	-
	Rent for Google space	60,000.00	12,000.00
	Travelling and Conveynce		1,000.00
	Printing & Stationery	15,792.00	2,658.84
	Legal charges including ROC charges	16,400.00	22,400.00
	Telephone Expenses	4,199.00	
	Bank Charges	247.18	383.50
	Round-off	0.26	-
	Ghy Biotech Park	55,747.56	-
	Project -1	73,058.00	
	Project -2	63,455.00	
	Total	428,199.00	184,800.00

Total

d on behalf of the Board

BW to formed IIISTAFA AHMED BARBHUIYA DIRECTOR DIN: 06465750 ANAMIKA BARUAH DIRECTOR DIN: 08276501

Director Foundation for Advancement of Essential Diagnostics (FAED) Gu:vahati-781029 (Assam)

Director Foundation for Advancement of Essential Diagnostics (FAED) Gu:/ahati-781029 (Assam)









Foundation for Advancement of Essential Diagnostics (FAED)

Guwahati Biotech Park, Amingaon Guwahati -781039 Assam, India

Phone numbers: 9864295480 (M), 9365061560 (M), 7906299636 (M) Email IDs: mabarbhuiya@faed.in, anamika@faed.in, amaj@faed.in Website: www.faed.in